Vaxart Inc., a privately held, clinical-stage biotechnology company that creates oral recombinant vaccines in the form of tablets instead of injections, had its representatives present details about its oral norovirus and seasonal influenza vaccines this week at the Ninth Vaccine & International Society of Vaccines Congress in Seoul.
The presentations will include information from the company’s two studies of these products. One will include data that shows the oral norovirus vaccine provokes a wider immune response than an injectable VLP VP1 vaccine. Another will emphasize data results from a Phase 1 clinical study that shows just one dose of the company’s H1N1 influenza tablet vaccine produced neutralizing antibodies within 92 percent of the study’s subjects.
Leesun Kim, a scientist from Vaxart, presented “Oral Immunization of a Norovirus Vaccine Leads to Superior Specific IgA Responses in Animals” Sunday and “Tablet Vaccine Platform Elicits Neutralizing Antibodies Without Impact on Pre-existing Immunity” Tuesday.
Vaxart has designed its vaccines to be founded on a versatile vector-based platform. The vaccines are meant to be used for a broad range of diseases including tablet vaccine candidates for norovirus, seasonal influenza, and Respiratory Syncytial Virus.
